Case Remain for Bal...
Health Care: Drugs
Cadence Pharmaceuticals Inc. (CADX: NASDAQ)
$6.87 -0.31 | -4.32%
05/20/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 58.33M | 82.61M | 112.18M | 75.86M |
| Receivables | 6.15M | 2.70M | 0.00 | 0.00 |
| Inventories | 6.50M | 1.39M | 485.00K | 0.00 |
| Other Current Assets | 1.15M | 90.00K | 36.00K | 31.26K |
| Total Current Assets | 76.52M | 132.93M | 136.04M | 84.05M |
| Property, Plant & Equipment, Gross | 7.33M | 14.59M | 11.40M | 9.98M |
| Accumulated Depreciation & Depletion | 5.36M | 4.02M | 2.41M | 1.68M |
| Property, Plant & Equipment, Net | 1.97M | 10.57M | 8.99M | 8.30M |
| Intangibles | 12.09M | 13.43M | 15.00M | 0.00 |
| Other Non-Current Assets | 7.11M | 7.23M | 3.76M | 209.45K |
| Total Non-Current Assets | 21.16M | 31.23M | 27.74M | 8.51M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 97.68M | 164.16M | 163.79M | 92.56M |
| Accounts Payable | 5.80M | 3.80M | 3.42M | 2.66M |
| Short Term Debt | 0.00 | 0.00 | 4.02M | 6.44M |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 22.05K |
| Total Current Liabilities | 21.00M | 16.04M | 14.72M | 16.86M |
| Long Term Debt | 28.82M | 28.70M | 24.65M | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 51.00K | 117.00K | 447.00K | 640.21K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 28.87M | 28.81M | 25.10M | 640.21K |
| Total Liabilities | 49.87M | 44.85M | 39.83M | 17.50M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 47.81M | 119.31M | 123.96M | 75.06M |
| Common Par | 9.00K | 9.00K | 6.00K | 5.05K |
| Additional Paid In Capital | 495.46M | 485.98M | 397.62M | 292.08M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -447.66M | -366.68M | -273.66M | -217.02M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 0.00 | 2.00K | 0.00 | 60.00 |
| Total Capitalization | 76.63M | 148.01M | 148.61M | 75.06M |
| Total Equity | 47.81M | 119.31M | 123.96M | 75.06M |
| Total Liabilities & Stock Equity | 97.68M | 164.16M | 163.79M | 92.56M |
| Total Common Shares Outstanding | 85.67M | 85.51M | 63.11M | 50.48M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 85.56M | 66.08M | 52.04M | 48.75M |
| Diluted Weighted Shares Outstanding | 85.56M | 66.08M | 52.04M | 48.75M |
| Number of Employees | 206 | 220 | 247 | 90 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with CADX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
- ContributorBreakout Stocks Of The Week...
- User8 Stocks Under $10 Making B...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- Contributor8 Stocks Below $10 To Avoid
Latest CADX Headlines from TheStreet
- 8 Stocks Under $10 Trending Sharply Higher 05.14.13 | 11:05 pm
- 4 Health Care Stocks Under $10 to Watch 04.16.13 | 03:04 pm
- 5 Stocks Poised for Breakouts 04.05.13 | 02:04 pm
- 5 Stocks Under $10 Triggering Breakouts 03.21.13 | 01:03 pm
- Stocks Under $5: Discount Drug Name
11.29.12 | 06:11 am - 8 Stocks Under $10 Making Big Moves 08.23.12 | 02:08 pm
- Cadence Pharmaceuticals' Management Presents At The 2012 Wedbush PACGROW Life Sciences Management Access Conference (Transcript) 08.14.12 | 09:08 pm
- Cadence Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript 08.03.12 | 01:08 am
- 7 Stocks Under $10 With Relative Strength 07.06.12 | 02:07 pm
- 8 Stocks Under $10 to Avoid at All Costs 12.23.11 | 12:12 pm
Press Releases for CADX
- Cadence Pharmaceuticals Announces Proposed Public Offering Of Common Stock - PR Newswire 11.08.10 | 06:11 am
Partner Headlines for CADX
- Cadence: Not Altering Sales Projections Or Rating In Aftermath Of Product Recall - Seeking Alpha 02.08.12 | 09:02 am
- Cadence Pharmaceuticals: Good For Patients, Bad For Investors - Seeking Alpha 12.26.11 | 08:12 am
- Wedbush Lowers Cadence PT to $10 from $15 - Benzinga 11.23.11 | 01:11 pm
- Company News for November 18, 2011 - Corporate Summary - Zacks 11.18.11 | 10:11 am
- Options Brief: Cadence Pharmaceuticals - Benzinga 07.15.11 | 01:07 pm
- Cadence: Not Unduly Concerned About ANDA Filing Against Ofirmev - Seeking Alpha 07.05.11 | 09:07 am
- 6 Speculative Biotech Stocks Smart Money Loves - Seeking Alpha 05.23.11 | 09:05 am
- Top 15 Most Undervalued Biotech Stocks By Analyst Target Price - Seeking Alpha 04.08.11 | 03:04 pm
- Future Biotech Superstars - Seeking Alpha 03.30.11 | 09:03 am
- Cadence Pharmaceuticals: A Rising Star - Seeking Alpha 03.13.11 | 09:03 am
